Related Experiment Video

Updated: Aug 23, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K

[The companion diagnostics of targeted therapy and immunotherapy for hepatocellular carcinoma]

X W Huang1, S H Liu1, J M Zhao1

  • 1Department of Pathology and Hepatology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.

Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology
|October 27, 2022
PubMed

Insights

Hepatocellular carcinoma (HCC) treatment is advancing with targeted therapies and immunotherapies. Companion diagnostics (CDx) are crucial for selecting patients and improving outcomes in advanced HCC.

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Pharmacogenomics

Context:

  • Hepatocellular carcinoma (HCC) presents a significant health challenge in China, characterized by high incidence and poor survival rates, particularly for unresectable advanced cases.
  • Limited effective therapeutic options exist for patients with advanced, unresectable HCC.
  • Emerging targeted and immunotherapy agents offer new treatment avenues for various solid tumors, including HCC.

Purpose:

  • To review companion diagnostics (CDx) technologies and their applications in hepatocellular carcinoma (HCC) targeting and immunotherapy.
  • To highlight the growing importance of CDx in personalized medicine for HCC.
  • To provide insights for precise diagnosis and treatment strategies in HCC.

Summary:

  • Companion diagnostics (CDx) are increasingly vital alongside targeted therapies and immunotherapies for advanced hepatocellular carcinoma (HCC).
  • CDx plays a key role in identifying patients eligible for specific treatments, thereby enhancing therapeutic efficacy.
  • This review explores current CDx technologies and their application in HCC, aiming to guide precise diagnostic and therapeutic approaches.

Impact:

  • Companion diagnostics are essential for optimizing the use of targeted and immunotherapy agents in HCC management.
  • The integration of CDx facilitates personalized treatment selection, potentially improving patient prognosis and survival rates.
  • This work offers a foundation for future advancements in precision oncology for hepatocellular carcinoma.

More Related Videos

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

273
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
639
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K